PRESS RELEASE

Q4 2024 — Press release

Q4 2024PDF · 17 pages854 KB
E A R N I N G S R E L E A S E
ELEVANCE HEALTH REPORTS FOURTH QUARTER AND
FULL YEAR 2024 RESULTS; SETS FULL YEAR 2025 OUTLOOK
• 4Q 2024 operating revenue of $45.0 billion; FY 2024 of $175.2 billion
• 4Q 2024 diluted EPS1 of $1.81; adjusted diluted EPS2 of $3.84
• FY 2024 diluted EPS1 of $25.68; adjusted diluted EPS2 of $33.04
• Projected FY 2025 GAAP diluted EPS1 to be in the range of $30.40 to $31.10
• Projected FY 2025 adjusted diluted EPS2 to be in the range of $34.15 to $34.85
• Quarterly dividend increased by 5% to $1.71 per share
Indianapolis, IN - January 23, 2025 - Elevance Health, Inc. (NYSE: ELV) reported fourth
quarter and full year 2024 results.
“As part of our commitment to elevating whole health and advancing health beyond healthcare,
we deliver value to the members and care providers we serve by ensuring simple, affordable,
and accessible care. Our fourth quarter results demonstrate tangible progress in improving our
operations in response to the dynamic environment facing the industry. As we look to 2025, we
remain resolute in our goal to simplify the healthcare experience, deepen the impact of
Carelon, and deploy innovative care models, positioning us to achieve sustainable growth over
the long run."
Gail K. Boudreaux
President and Chief Executive Officer
1. Earnings per diluted share ("EPS").
2. Refer to GAAP reconciliation tables on pages 13 and 14 herein for reconciliation of GAAP to adjusted measures.
1

-- 1 of 17 --

Elevance Health
Consolidated Enterprise Highlights
(Unaudited)
(In billions) Three Months Ended Twelve Months Ended
December 31,
2024 December 31,
2023 December 31,
2024 December 31,
2023
Operating Revenue1 $45.0 $42.5 $175.2 $170.2
Operating Gain1,2 $0.7 $1.3 $7.9 $8.5
Adjusted Operating Gain1,3 $1.0 $1.4 $9.3 $9.4
Operating Margin1 1.5 % 3.0 % 4.5 % 5.0 %
Adjusted Operating Margin1 2.3 % 3.2 % 5.3 % 5.5 %
1. See “Basis of Presentation” on page 5 herein.
2. Operating Gain for the three and twelve months ended December 31, 2024, and December 31, 2023, include items that are excluded from
adjusted shareholders' net income. See "GAAP Reconciliation" on pages 13 and 14 herein.
3. Adjusted Operating Gain for the three and twelve months ended December 31, 2024, and December 31, 2023, exclude items that are excluded
from adjusted shareholders' net income. See "GAAP Reconciliation" on pages 13 and 14 herein.
Operating revenue was $45.0 billion in the fourth quarter of 2024, an increase of $2.5 billion, or 6
percent compared to the prior year quarter. Operating revenue was $175.2 billion in 2024, an increase of
$5.0 billion, or 3 percent. The increase in revenue for the quarter and year was driven by higher
premium yields in our Health Benefits segment, acquisitions completed in 2024, and growth in
CarelonRx product revenue, partially offset by membership attrition in our Medicaid business.
The benefit expense ratio was 92.4 percent in the fourth quarter, an increase of 320 basis points
compared to the prior year period, and 88.5 percent for the full year, an increase of 150 basis points year
over year. The increases were driven primarily by higher Medicaid medical cost trends. Days in Claims
Payable was 42.9 days as of December 31, 2024, a slight increase of 0.1 days from September 30, 2024,
and a decrease of 4.4 days compared to December 31, 2023.
The operating expense ratio was 10.7 percent in the fourth quarter and 11.4 percent for the full year. On
an adjusted basis, the corresponding operating expense ratios were 9.9 percent and 10.6 percent. The
improvements in the adjusted operating expense ratio over prior year periods of 170 basis points and 70
basis points, respectively, reflect disciplined cost management and enhanced efficiency.
Cash Flow & Balance Sheet
Operating cash flow was $5.8 billion in 2024, approximately 1.0 times GAAP net income. As of
December 31, 2024, cash and investments at the parent company totaled approximately $2.4 billion.
During the fourth quarter of 2024, the Company repurchased 4.5 million shares of its common stock for
$1.8 billion, at a weighted average price of $401.29, and paid a quarterly dividend of $1.63 per share,
representing a distribution of cash totaling $373 million. As of December 31, 2024, the Company had
approximately $9.3 billion of Board approved share repurchase authorization remaining.
2

-- 2 of 17 --

Health Benefits is comprised of Individual, Employer Group risk-based, Employer Group fee-based,
BlueCard®, Medicare, Medicaid, and Federal Employee Program businesses.
Health Benefits
Reportable Segment Highlights
(Unaudited)
(In billions) Three Months Ended Twelve Months Ended
December 31,
2024 December 31,
2023 December 31,
2024 December 31,
2023
Operating Revenue1 $37.6 $36.5 $150.3 $148.6
Operating Gain1,2 $0.2 $0.8 $6.2 $6.9
Adjusted Operating Gain1,3 $0.3 $0.8 $6.3 $6.9
Operating Margin1 0.6 % 2.1 % 4.2 % 4.6 %
Adjusted Operating Margin1 0.7 % 2.1 % 4.2 % 4.6 %
1. See “Basis of Presentation” on page 5 herein.
2. Operating Gain for the three and twelve months ended December 31, 2024 include items that are excluded from adjusted shareholders' net
income. See "GAAP Reconciliation" on pages 13 and 14 herein.
3. Operating gain for both the three and twelve months ended December 31, 2024 includes $66 million of business dispositions and related items
adjusted out of adjusted shareholders' net income for the Health Benefits segment.
Health Benefits segment operating revenue was $37.6 billion in the fourth quarter of 2024, an increase
of $1.0 billion, or 3 percent compared to the fourth quarter of 2023. Operating revenue was $150.3
billion in 2024, an increase of $1.7 billion, or 1 percent. The increases for the quarter and year were
driven primarily by higher premium yields, partially offset by membership attrition in our Medicaid
business.
Operating gain totaled $0.2 billion in the fourth quarter of 2024 and $6.2 billion for the full year. On an
adjusted basis, operating gain was $0.3 billion in the fourth quarter of 2024 and $6.3 billion for the full
year. Adjusted operating gain in both periods was impacted primarily by higher cost trend in Medicaid
related to redeterminations.
Medical membership totaled approximately 45.7 million as of December 31, 2024, a decrease of 1.1
million, or 2 percent year over year, driven by attrition in our Medicaid business, partially offset by
growth in Employer Group fee-based and Affordable Care Act health plan membership.
3

-- 3 of 17 --

Carelon is comprised of CarelonRx and Carelon Services.
Carelon
Reportable Segment Highlights
(Unaudited)
(In billions) Three Months Ended Twelve Months Ended
December 31,
2024 December 31,
2023 December 31,
2024 December 31,
2023
Operating Revenue1,2 $14.7 $12.4 $53.9 $48.0
Operating Gain1 $0.6 $0.6 $2.9 $2.7
Adjusted Operating Gain1,3 $0.8 $0.6 $3.1 $2.7
Operating Margin1 3.9 % 4.8 % 5.4 % 5.5 %
Adjusted Operating Margin1 5.3 % 4.8 % 5.8 % 5.5 %
1. See “Basis of Presentation” on page 5 herein.
2. Operating revenue for both the three and twelve months ended December 31, 2024 includes $0.8 of revenue related to business dispositions and
related items that have been excluded from adjusted operating gain.
3. Operating gain for both the three and twelve months ended December 31, 2024 includes $0.2 of business dispositions and related items adjusted
out of adjusted shareholders' net income for the Carelon segment.
Operating revenue for Carelon was $14.7 billion in the fourth quarter of 2024, an increase of $2.3
billion, or 19 percent compared to the prior year period. Operating revenue was $53.9 billion in 2024, an
increase of $5.9 billion, or 12 percent. The increases for the quarter and the year were driven by the
launch and growth of risk-based capabilities in Carelon Services and acquisitions completed in 2024.
Operating gain for Carelon totaled $0.6 billion in the fourth quarter, effectively flat year over year;
however, on an adjusted basis, operating gain was $0.8 billion, an increase of $0.2 billion, or 32 percent.
The increase for the fourth quarter of 2024 was driven by higher pharmacy product revenue. On a full
year basis, operating gain was $2.9 billion in 2024, an increase of $0.2 billion, or 9 percent. Similarly,
on an adjusted basis, operating gain was $3.1 billion, an increase of $0.4 billion, or 17 percent.
4

-- 4 of 17 --

Quarterly Dividend
On January 22, 2025, the Audit Committee of the Company's Board of Directors declared a first quarter
2025 dividend to shareholders of $1.71 per share. The first quarter dividend is payable on March 25,
2025, to shareholders of record at the close of business on March 10, 2025.
About Elevance Health
Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity.
The company supports consumers, families, and communities across the entire healthcare journey –
connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s
companies serve approximately 112 million consumers through a diverse portfolio of industry-leading
medical, pharmacy, behavioral, clinical, home health, and complex care solutions. For more information,
please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on
LinkedIn.
Conference Call and Webcast
Management will host a conference call and webcast today at 8:30 a.m. Eastern Standard Time (“EST”)
to discuss the company’s fourth quarter and full year 2024 results and 2025 outlook. The conference call
should be accessed at least 15 minutes prior to the start of the call with the following numbers:
888-947-9963 (Domestic) 866-405-7292 (Domestic Replay)
312-470-0178 (International) 203-369-0604 (International Replay)
The access code for today's conference call is 3972058. There is no access code for the replay. The
replay will be available from 11:30 a.m. EST today, until the end of the day on February 21, 2025. The
call will also be available through a live webcast at www.elevancehealth.com under the “Investors” link.
A webcast replay will be available following the call.
Basis of Presentation
1. Operating revenue and operating gain/loss are the key measures used by management to evaluate
performance in each of its reporting segments, allocate resources, set incentive compensation
targets and to forecast future operating performance. Operating gain/loss is calculated as total
operating revenue less benefit expense, cost of products sold and operating expense. It does not
include net investment income, net gains/losses on financial instruments, interest expense,
amortization of other intangible assets, gains/losses on extinguishment of debt or income taxes, as
these items are managed in a corporate shared service environment and are not the responsibility of
operating segment management. Refer to pages 13 and 14 for the GAAP reconciliation tables.
2. Operating margin is defined as operating gain divided by operating revenue.
Elevance Health Contacts:
Investor Relations Media
Nathan Rich Leslie Porras
Investor.Relations@elevancehealth.com Leslie.Porras@elevancehealth.com
5

-- 5 of 17 --

Elevance Health
Earnings Release Financial Schedules and Supplementary Information
Quarter & Year Ended December 31, 2024
• Membership and Other Metrics
• Quarterly & Full Year Consolidated Statements of Income
• Condensed Consolidated Balance Sheet
• Condensed Consolidated Statement of Cash Flows
• Supplemental Financial Information - Reportable Segments
• Supplemental Financial Information - Reconciliation of Medical Claims Payable
• Reconciliation of Non-GAAP Financial Measures
• Financial Guidance Summary
• Membership Guidance Summary
6

-- 6 of 17 --

Elevance Health
Membership and Other Metrics
(Unaudited)
Change from
Medical Membership (in thousands) December 31,
2024 December 31,
2023 September 30,
2024 December 31,
2023 September 30,
2024
Individual . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,287 1,025 1,299 25.6 % (0.9) %
Employer Group Risk-Based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,713 3,756 3,672 (1.1) % 1.1 %
Commercial Risk-Based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,000 4,781 4,971 4.6 % 0.6 %
BlueCard®1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,630 6,706 6,677 (1.1) % (0.7) %
Employer Group Fee-Based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20,569 20,227 20,589 1.7 % (0.1) %
Commercial Fee-Based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27,199 26,933 27,266 1.0 % (0.2) %
Medicare Advantage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,066 2,047 2,047 0.9 % 0.9 %
Medicare Supplement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 891 923 894 (3.5) % (0.3) %
Total Medicare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,957 2,970 2,941 (0.4) % 0.5 %
Medicaid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8,917 10,503 8,926 (15.1) % (0.1) %
Federal Employee Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,661 1,642 1,656 1.2 % 0.3 %
Total Medical Membership . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45,734 46,829 45,760 (2.3) % (0.1) %
Other Membership (in thousands)
Dental Members . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7,282 6,820 7,021 6.8 % 3.7 %
Dental Administration Members . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,887 1,729 1,878 9.1 % 0.5 %
Vision Members . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10,419 9,944 10,382 4.8 % 0.4 %
Medicare Part D Standalone Members . . . . . . . . . . . . . . . . . . . . . . . . . . 256 260 258 (1.5) % (0.8) %
Other Metrics (in millions)
CarelonRx Quarterly Adjusted Scripts . . . . . . . . . . . . . . . . . . . . . . . . . . . 82.9 78.0 80.2 6.3 % 3.4 %
Carelon Services Consumers Served . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101.1 103.3 101.3 (2.1) % (0.2) %
1. BlueCard® membership for the three months ended December 31, 2023, is restated to align to the Blue Cross Blue Shield Association reporting methodology. For the three months ended December 31, 2023,
BlueCard® membership has been restated lower by 132.
7

-- 7 of 17 --

Elevance Health
Consolidated Statements of Income
(Unaudited)
(In millions, except per share data)
Three Months Ended
December 31
Twelve Months Ended
December 31
2024 2023 Change 2024 2023 Change
Revenues
Premiums . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 36,245 $ 35,138 3.2 % $ 144,166 $ 142,854 0.9 %
Product revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,714 5,394 24.5 % 22,630 19,452 16.3 %
Service fees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,030 1,922 5.6 % 8,408 7,903 6.4 %
Total operating revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44,989 42,454 6.0 % 175,204 170,209 2.9 %
Net investment income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 527 529 (0.4) % 2,051 1,825 12.4 %
Net losses on financial instruments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (74) (336) NM (445) (694) NM
Gain on sale of business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — — NM 201 — NM
Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45,442 42,647 6.6 % 177,011 171,340 3.3 %
Expenses
Benefit expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33,500 31,334 6.9 % 127,567 124,330 2.6 %
Cost of products sold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,012 4,837 24.3 % 19,750 17,293 14.2 %
Operating expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,804 4,999 (3.9) % 20,025 20,087 (0.3) %
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 340 259 31.3 % 1,185 1,030 15.0 %
Amortization of other intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180 217 (17.1) % 580 885 (34.5) %
Total expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44,836 41,646 7.7 % 169,107 163,625 3.4 %
Income before income tax expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 606 1,001 (39.5) % 7,904 7,715 2.4 %
Income tax expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193 170 13.5 % 1,933 1,724 12.1 %
Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 413 831 (50.3) % 5,971 5,991 (0.3) %
Net loss (income) attributable to noncontrolling interests . . . . . . . . . . . . . 5 25 NM 9 (4) NM
Shareholders' net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 418 $ 856 (51.2) % $ 5,980 $ 5,987 (0.1) %
Shareholders' earnings per diluted share . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 1.81 $ 3.63 (50.1) % $ 25.68 $ 25.22 1.8 %
Diluted shares . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231.1 235.8 (2.0) % 232.9 237.4 (1.9) %
Benefit expense as a percentage of premiums . . . . . . . . . . . . . . . . . . . . . . . . . 92.4 % 89.2 % 320 bp 88.5 % 87.0 % 150 bp
Operating expense as a percentage of total operating revenue . . . . . . . . . . . . . 10.7 % 11.8 % (110) bp 11.4 % 11.8 % (40) bp
Income before income tax expense as a percentage of total revenue . . . . . . . . 1.3 % 2.3 % (100) bp 4.5 % 4.5 % — bp
"NM" = calculation not meaningful
8

-- 8 of 17 --

Elevance Health
Condensed Consolidated Balance Sheet
(In millions)
December 31,
2024 December 31,
2023
Assets (Unaudited)
Current assets:
Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $8,288 $6,526
Fixed maturity and equity securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26,393 29,843
Premium and other receivables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18,796 17,865
Other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,759 5,795
Assets held for sale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 490 —
Total current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58,726 60,029
Long-term investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10,784 6,983
Property and equipment, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,652 4,359
Goodwill and other intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40,371 35,590
Other noncurrent assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,140 1,967
Total assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $116,673 $108,928
Liabilities and equity
Liabilities
Current liabilities:
Medical claims payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $15,626 $16,111
Short-term borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 365 225
Current portion of long-term debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,649 1,649
Other current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22,572 23,806
Liabilities held for sale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153 —
Total current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40,365 41,791
Long-term debt, less current portion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29,218 23,246
Other noncurrent liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,664 4,486
Total liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75,247 69,523
Total shareholders’ equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41,315 39,306
Noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111 99
Total equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41,426 39,405
Total liabilities and equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $116,673 $108,928
9

-- 9 of 17 --

Elevance Health
Condensed Consolidated Statement of Cash Flows
(Unaudited)
(In millions)
Twelve Months Ended
December 31
2024 2023
Operating activities
Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 5,971 $ 5,991
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,393 1,745
Share-based compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191 289
Changes in operating assets and liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (1,719) (534)
Other non-cash items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (28) 570
Net cash provided by operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,808 8,061
Investing activities
Proceeds from sale/ (purchases) of investments, net of maturities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 586 (2,700)
Net purchases of subsidiaries, net of cash acquired/sold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (4,446) (1,552)
Purchases of property and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (1,256) (1,296)
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (51) (24)
Net cash used in investing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (5,167) (5,572)
Financing activities
Net change in short-term and long-term borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,200 626
Repurchase and retirement of common stock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (2,900) (2,676)
Cash dividends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (1,508) (1,395)
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (599) 96
Net cash provided by (used in) financing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,193 (3,349)
Effect of foreign exchange rates on cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (6) (1)
Change in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,828 (861)
Cash and cash equivalents at beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,526 7,387
Less cash and equivalents included in assets held for sale at end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (66) —
Cash and cash equivalents at end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $8,288 $6,526
10

-- 10 of 17 --

REPORTABLE SEGMENTS
Elevance Health has four reportable segments: Health Benefits (comprised of Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid, and Federal
Employee Program businesses); CarelonRx; Carelon Services; and Corporate & Other (comprised of businesses that do not individually meet the quantitative thresholds for an operating division as
well as corporate expenses not allocated to our other reportable segments).
Elevance Health
Reportable Segment Highlight Details
(Unaudited)
(In millions) Three Months Ended December 31 Twelve Months Ended December 31
2024 2023 Change 2024 2023 Change
Operating Revenue
Health Benefits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $37,580 $36,547 2.8 % $150,275 $148,571 1.1 %
CarelonRx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9,977 8,827 13.0 % 35,961 33,835 6.3 %
Carelon Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,769 3,574 33.4 % 17,961 14,147 27.0 %
Corporate & Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (14) 181 NM5 309 479 (35.5) %
Eliminations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (7,323) (6,675) 9.7 % (29,302) (26,823) 9.2 %
Total Operating Revenue1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $44,989 $42,454 6.0 % $175,204 $170,209 2.9 %
Operating Gain (Loss)
Health Benefits2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $207 $767 (73.0) % $6,243 $6,888 (9.4) %
CarelonRx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 533 490 8.8 % 2,172 1,975 10.0 %
Carelon Services2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 102 (65.7) % 717 680 5.4 %
Corporate & Other2,3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (102) (75) NM5 (1,270) (1,044) NM5
Total Operating Gain1,4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $673 $1,284 (47.6) % $7,862 $8,499 (7.5) %
Operating Margin
Health Benefits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.6 % 2.1 % (150) bp 4.2 % 4.6 % (40) bp
CarelonRx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.3 % 5.6 % (30) bp 6.0 % 5.8 % 20 bp
Carelon Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.7 % 2.9 % (220) bp 4.0 % 4.8 % (80) bp
Total Operating Margin1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.5 % 3.0 % (150) bp 4.5 % 5.0 % (50) bp
1. See “Basis of Presentation” on page 5 herein.
2. Operating gain for the three and twelve months ended December 31, 2024 included $281 of business dispositions and related items excluded from adjusted shareholders' net income; including $215 for the Carelon
Services segment; and $66 for the Health Benefits segment. Operating gain for the three and twelve months ended December 31, 2024 included $66 and $224, respectively, of transaction and integration related
costs, all of which resides in the Corporate & Other reportable segment. Operating gain for the three and twelve months ended December 31, 2024 included $12 and $692, respectively, of litigation and settlement
expenses, all of which resides in the Corporate & Other reportable segment. Operating gain for the twelve months ended December 31, 2024 included $268 of business optimization charges which reside in the
Corporate & Other reportable segment.
3. Operating gain for the three and twelve months ended December 31, 2023 included; $59 and $213, respectively, of transaction and integration related costs; $22 and $719, respectively, of business optimization
charges; and ($7) and ($2), respectively, of litigation and settlement expenses.
4. Operating Gain for the three and twelve months ended December 31, 2024, and December 31, 2023, included items excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on pages 13 and
14 herein.
5. "NM" = calculation not meaningful.
11

-- 11 of 17 --

Elevance Health
Reconciliation of Medical Claims Payable
Years Ended December 31
2024 2023 2022
(In millions) (Unaudited)
Gross medical claims payable, beginning of year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 15,865 $ 15,348 $ 13,282
Ceded medical claims payable, beginning of year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (7) (6) (21)
Net medical claims payable, beginning of year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15,858 15,342 13,261
Business combinations and purchase adjustments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143 — 133
Net incurred medical claims:
Current year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125,370 121,798 113,414
Prior years redundancies1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (1,731) (1,571) (869)
Total net incurred medical claims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123,639 120,227 112,545
Net payments attributable to:
Current year medical claims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111,051 107,146 98,997
Prior years medical claims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13,142 12,565 11,600
Total net payments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124,193 119,711 110,597
Net medical claims payable, end of year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15,447 15,858 15,342
Ceded medical claims payable, end of year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 7 6
Gross medical claims payable, end of year2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 15,460 $ 15,865 $ 15,348
Current year medical claims paid as a percentage
of current year net incurred medical claims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88.6 % 88.0 % 87.3 %
Prior year redundancies in the current year as a percentage of prior year
net medical claims payable less prior year redundancies in the current year . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12.3 % 11.4 % 7.0 %
Prior year redundancies in the current year as a
percentage of prior year net incurred medical claims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.4 % 1.4 % 0.9 %
1. Negative amounts reported for net incurred medical claims related to prior years result from claims being settled for amounts less than originally estimated.
2. Excludes insurance lines other than short duration.
12

-- 12 of 17 --

Elevance Health
GAAP Reconciliation
(Unaudited)
This document references non-GAAP measures, including “Adjusted Shareholders’ Net Income,” “Adjusted Shareholders’ Net Income Per Share,” “Adjusted EPS,” “Adjusted Operating Gain,” “Adjusted Operating Expense”
and “Adjusted Operating Expense Ratio,” which are non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and are not intended to
be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP are available below. In
addition to these non-GAAP measures, references are made to the measures “Operating Revenue” and “Operating Gain/Loss,” “Operating Margin” and “Adjusted EPS”. Operating revenue and operating gain/loss are the key
measures used by management to evaluate performance in each of its reportable segments, allocate resources, set incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated
as total operating revenue less benefit expense, cost of products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other
intangible assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. Each of
these measures is provided to further aid investors in understanding and analyzing Elevance Health’s operating and financial results. A reconciliation of Operating Revenue to Total Revenue is set forth in the Consolidated
Statements of Income herein. A reconciliation of the non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP, together with a reconciliation of reportable segments operating gain
to income before income tax expense, is provided below. Prior amounts may be grouped differently to conform to the current presentation. Net adjustment items per share may not sum due to rounding. A reconciliation of
Operating Revenue to Total Revenue is set forth in the Consolidated Statements of Income herein.
Three Months Ended
December 31 Twelve Months Ended
December 31
(In millions, except per share data) 2024 2023 Change 2024 2023 Change
Shareholders' net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 418 $ 856 (51.2) % $ 5,980 $ 5,987 (0.1) %
Add / (Subtract):
Business dispositions and related items1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 281 — 281 —
Amortization of other intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180 217 580 885
Net losses on financial instruments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74 336 445 694
Transaction and integration related costs2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66 59 224 213
Litigation and settlement expenses2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 (7) 692 (2)
Gain on sale of business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — — (201) —
Business optimization charges2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — 22 268 719
Tax impact of non-GAAP adjustments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (143) (158) (575) (628)
Net adjustment items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 470 469 1,714 1,881
Adjusted shareholders' net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 888 $ 1,325 (33.0) % $ 7,694 $ 7,868 (2.2) %
Shareholders' earnings per diluted share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 1.81 $ 3.63 (50.1) % $ 25.68 $ 25.22 1.8 %
Add / (Subtract):
Business dispositions and related items1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.22 — 1.21 —
Amortization of other intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.78 0.92 2.49 3.73
Net losses on financial instruments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.32 1.42 1.91 2.92
Transaction and integration related costs2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.29 0.25 0.96 0.90
Litigation and settlement expenses2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.05 (0.03) 2.97 (0.01)
Gain on sale of business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — — (0.86) —
Business optimization charges2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — 0.09 1.15 3.03
Tax impact of non-GAAP adjustments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (0.62) (0.67) (2.47) (2.65)
Net adjustment items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.03 1.99 7.36 7.92
Adjusted shareholders' earnings per diluted share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 3.84 $ 5.62 (31.7) % $ 33.04 $ 33.14 (0.3) %
Three Months Ended
December 31 Twelve Months Ended
December 31
(In millions) 2024 2023 Change 2024 2023 Change
Income before income tax expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 606 $ 1,001 (39.5) % $ 7,904 $ 7,715 2.4 %
Net investment income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (527) (529) (2,051) (1,825)
Gain on sale of business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — — (201) —
Net losses on financial instruments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74 336 445 694
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 340 259 1,185 1,030
Amortization of other intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180 217 580 885
Reportable segments operating gain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 673 $ 1,284 (47.6) % $ 7,862 $ 8,499 (7.5) %
1. Adjustment item resides in the Health Benefits and Carelon Services reportable segments.
2. Adjustment item resides in the Corporate & Other reportable segment.
13

-- 13 of 17 --

Elevance Health
GAAP Reconciliation
(Unaudited)
Three Months Ended
December 31 Twelve Months Ended
December 31
(In millions) 2024 2023 Change 2024 2023 Change
Reportable segments operating gain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 673 $ 1,284 (47.6) % $ 7,862 $ 8,499 (7.5) %
Add / (Subtract):
Business dispositions and related items1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 281 — 281 —
Transaction and integration related costs2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66 59 224 213
Litigation and settlement expenses2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 (7) 692 (2)
Business optimization charges2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — 22 268 719
Net adjustment items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 359 74 1,465 930
Reportable segments adjusted operating gain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 1,032 $ 1,358 (24.0) % $ 9,327 $ 9,429 (1.1) %
Three Months Ended
December 31 Twelve Months Ended
December 31
(In millions) 2024 2023 Change 2024 2023 Change
Operating expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 4,804 $ 4,999 (3.9) % $ 20,025 $ 20,087 (0.3) %
Add / (Subtract):
Business dispositions and related items1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (281) — (281) —
Transaction and integration related costs2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (66) (59) (224) (213)
Litigation and settlement expenses2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (12) 7 (692) 2
Business optimization charges2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — (22) (268) (719)
Net adjustment items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (359) (74) (1,465) (930)
Adjusted operating expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 4,445 $ 4,925 (9.7) % $ 18,560 $ 19,157 (3.1) %
Operating revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 44,989 $ 42,454 6.0 % $ 175,204 $ 170,209 2.9 %
Operating expense ratio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.7 % 11.8 % (110) bp 11.4 % 11.8 % (40) bp
Adjusted operating expense ratio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.9 % 11.6 % (170) bp 10.6 % 11.3 % (70) bp
Full Year
2025 Outlook
Shareholders' earnings per diluted share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $30.40 to $31.10
Add / (Subtract):
Amortization of other intangibles3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $2.57
Net losses on financial instruments3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $1.12
Transaction and integration related costs2,3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $1.11
Litigation and settlement expenses2,3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $0.04
Tax impact of non-GAAP adjustments3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Approximately ($1.09)
Net adjustment items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $3.75
Adjusted shareholders' earnings per diluted share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $34.15 to $34.85
1. Adjustment item resides in the Health Benefits and Carelon Services reportable segments.
2. Adjustment item resides in the Corporate & Other reportable segment.
3. Adjustment item represents the midpoint of a projected range and serves as the estimated full year adjustment amount.
14

-- 14 of 17 --

Elevance Health
Financial Guidance Summary
(Unaudited)
Full Year 2024 Actual Full Year 2025 Outlook
Premium Revenue $144.2 billion Low double digit growth
Product Revenue $22.6 billion Low single digit growth
Service Fees $8.4 billion Approximately flat
Total Operating Revenue $175.2 billion High single to low double digit growth
Benefit Expense Ratio 88.5% 89.1% +/- 50 bps
Adjusted Operating Expense Ratio 10.6% 10.4% +/- 50 bps
Adjusted Operating Gain $9.3 billion $9.55 - $9.85 billion
Other Pre-Tax Items:
Net Investment income $2,051 million $1,875 million
Interest Expense ($1,185) million ($1,475) million
Amortization of Intangible Assets ($580) million ($580) million
Net Pre-Tax Income (Expense) $286 million ($180) million
Adjusted Effective Tax Rate 24.6% 22.0% - 24.0%
GAAP Diluted EPS $25.68 $30.40 - $31.10
Adjusted Diluted EPS $33.04 $34.15 - $34.85
Diluted Shares 232.9 million 225 - 226 million
Operating Cash Flow $5.8 billion Approximately $8.0 billion
Segment Level Guidance Metrics
Operating Revenue Growth Rate
Health Benefits $150.3 billion High single digit growth
CarelonRx $36.0 billion Mid teens growth
Carelon Services $18.0 billion Greater than 50% growth
GAAP Operating Margin vs. 2024
Health Benefits 4.2% (50) - (25) bps
CarelonRx 6.0% 0 - 20 bps
Carelon Services 4.0% (100) - (50) bps
15

-- 15 of 17 --

Elevance Health
Membership Guidance Summary
(Unaudited)
Full Year 2024 Actual Full Year 2025 Outlook
Year-End Medical Enrollment (in 000s)
Commercial Fee-Based 27,199 27,300 - 27,600
Commercial Risk-Based 5,000 5,150 - 5,350
Medicaid 8,917 8,600 - 8,900
Medicare Advantage 2,066 2,200 - 2,250
Medicare Supplement 891 Approximately 850
Federal Employee Program 1,661 Approximately 1,650
Fee-Based 27,199 27,300 - 27,600
Risk-Based 18,535 18,450 - 19,000
Total 45,734 45,750 - 46,600
16

-- 16 of 17 --

Forward-Looking Statements
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-
looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,”
“feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify
forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions;
statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future
performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control,
that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are
cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully
review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from
time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not update
or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include,
but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium
rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new
or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy
services and other diversified products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security
incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related
thereto; failure to effectively maintain and modernize our information systems, or failure of our information systems or technology, including artificial
intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market
conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to
changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid
programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve
improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with respect to revenue
received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government
investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing
healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance
by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; the effects of any negative publicity related to
the health benefits industry in general or us in particular; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible
impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions
in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our
common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential
negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact
our access to or further increase the cost of financing; a downgrade in our financial strength ratings; events that may negatively affect our licenses
with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international
operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.
17

-- 17 of 17 --